Funding Archives

News and Trends 12 May 2023

Cell and gene therapy company NewBiologix exits stealth with $50M

NewBiologix SA has emerged from stealth as a technology innovation company developing a proprietary and breakthrough platform for the advanced engineering of cell lines used to manufacture gene and cell therapies. The company’s DNA-based platform is being developed to address key manufacturing challenges associated with the production of recombinant adeno-associated virus (rAAV) vectors used to […]

May 12, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 9 May 2023

Gene & cell therapy manufacturer Ascend launches with more than $130M

Ascend Gene & Cell Therapies (Ascend), a company innovating manufacturing processes to improve quality, potency, safety and cost enabling better reach for gene therapy technologies, has launched as a facilitator for gene therapy companies to help translate product ideas into clinical programs. Ascend Gene & Cell Therapies offers process development, clinical manufacturing, and analytical and […]

May 9, 2023 - 2 minutesmins - By Jim Cornall

In Depth 5 May 2023

The biggest private biotech investments in April 2023

April 2023 saw the companies Orbital Therapeutics, Sangon Biotech, and Alentis Therapeutics bag the biggest biotech investments of the month. Around the world, oncology, drug discovery, food and biomaterials attracted the biggest funding rounds. With reports of venture capital investments in biotech and pharma hitting a more than three-year low last quarter, private biotech fundraising […]

May 5, 2023 - 3 minutesmins - By Willow Shah-Neville

News and Trends 5 May 2023

Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the completion of a $90 million Series A financing. The funding was led by OrbiMed and RA Capital Management with participation from Invus. The financing will support the development of a pipeline of novel […]

May 5, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Mezzion Pharma raises $40M for treatment option for heart surgery patients

Mezzion Pharma, a rare disease focused pharmaceutical company, has secured nearly $40 million to fund FUEL-2, its confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion Pharma is looking to bring to market JURVIGO (udenafil), a highly selective, unique and potent phosphodiesterase type 5 (PDE-5) inhibitor, […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

ADC firm Adcentrx Therapeutics aims for clinic after $38M boost

Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx’s financial advisors. Adcentrx Therapeutics intends to use the […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Vedanta Biosciences raises $106.5M for microbiome therapy

Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million. The funds will support pivotal-stage development of the U.S. company’s lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a phase 2 study of VE202 for ulcerative colitis, among […]

April 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 24 Apr 2023

LifeArc launches £40M funding call to create Translational Rare Disease Centres

LifeArc is inviting applications from academic institutions for its latest £40 million ($49.8 million) initiative to fund four or five new Translational Rare Disease Centres in the U.K., along with a separate co-ordinating hub. LifeArc, which is a self-funded, non-profit medical research charity, specializes in early-stage translation – the advancement of scientific discoveries towards patient […]

April 24, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 20 Apr 2023

Hasten raises $315M for acquisitions and pipeline development

CBC Group, Asia’s largest healthcare-dedicated investment firm headquartered in Singapore, and Hasten Biopharmaceutic Company Limited, have completed a $315 million fundraising round for Hasten. Hasten is a Chinese biopharma company backed by CBC, Hefei Industry Investment Group, and Feidong County of Hefei City. The fundraising round was co-led by CBC and Abu Dhabi sovereign wealth […]

April 20, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Calida Therapeutics, a preclinical stage biotech company specializing in thrombo-inflammatory disorders, has announced its incorporation in Paris, France. Calida Therapeutics has already raised €2 million ($2.17 million) in seed funding from venture capital company AdBio partners. The funds will be used to conduct additional in vivo proofs of concept and select a lead candidate. Calida […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 11 Apr 2023

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Vitarka Therapeutics, which focuses on non-viral drug delivery technology, has raised £1.27 million ($1.58 million) in equity from venture capital firm SOSV, the UK Innovation & Science Seed Fund (UK12S) and grant funding from Innovate UK. Founded in 2021 by Vineeta Tripathi, Vitarka Therapeutics is developing combination medicines using RNAi therapies and a non-viral drug […]

April 11, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 5 Apr 2023

Cure Ventures launches with $350M to support life sciences companies

Cure Ventures, a life sciences venture capital firm focusing on company formation around groundbreaking curative technologies, has closed its inaugural fund, Cure Ventures Fund I, L.P., at its targeted hard-cap of $350 million in capital commitments. The fund is supported by a syndicate of U.S. and internationally-based investors that includes state and city public pension […]

April 5, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Funding

Cell and gene therapy company NewBiologix exits stealth with $50M

Gene & cell therapy manufacturer Ascend launches with more than $130M

The biggest private biotech investments in April 2023

Convergent Therapeutics to use $90M funding to treat cancer with radiopharmaceuticals

Mezzion Pharma raises $40M for treatment option for heart surgery patients

ADC firm Adcentrx Therapeutics aims for clinic after $38M boost

Vedanta Biosciences raises $106.5M for microbiome therapy

LifeArc launches £40M funding call to create Translational Rare Disease Centres

Hasten raises $315M for acquisitions and pipeline development

Calida Therapeutics launches to tackle thrombo-inflammatory disorders

Intracellular drug delivery startup Vitarka Therapeutics raises £1.27M

Cure Ventures launches with $350M to support life sciences companies

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!